BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9137501)

  • 1. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.
    Kim SJ; Shiba E; Taguchi T; Watanabe T; Tanji Y; Kimoto Y; Izukura M; Takai SI
    Anticancer Res; 1997; 17(2B):1373-8. PubMed ID: 9137501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.
    Schewe DM; Biller T; Maurer G; Asangani IA; Leupold JH; Lengyel ER; Post S; Allgayer H
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8538-48. PubMed ID: 16361535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
    Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
    Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue.
    Bianchi E; Cohen RL; Thor AT; Todd RF; Mizukami IF; Lawrence DA; Ljung BM; Shuman MA; Smith HS
    Cancer Res; 1994 Feb; 54(4):861-6. PubMed ID: 8313371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative u-PAR gene expression in bone marrow indicates the potential power of recurrence in breast cancer cases.
    Mimori K; Kataoka A; Yamaguchi H; Masuda N; Kosaka Y; Ishii H; Ohno S; Mori M
    Ann Surg Oncol; 2009 Jul; 16(7):2035-41. PubMed ID: 19404710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
    Paciucci R; Torà M; Díaz VM; Real FX
    Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
    Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
    J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
    Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer.
    Maurer GD; Leupold JH; Schewe DM; Biller T; Kates RE; Hornung HM; Lau-Werner U; Post S; Allgayer H
    Clin Cancer Res; 2007 Feb; 13(4):1123-32. PubMed ID: 17317820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study.
    Kim SJ; Shiba E; Ishii H; Inoue T; Taguchi T; Tanji Y; Kimoto Y; Izukura M; Takai S
    Anticancer Res; 1997; 17(3C):2319-23. PubMed ID: 9216709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.